Nyxoah 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Nyxoah S.A. reported 3rd quarter 2026 net revenue of €9.2 million, up 365% over the 3rd quarter of 2025 and 19% sequentially over the 2nd quarter of 2026.
- U.S. net revenue was €6.7 million, representing 29% sequential growth; international net revenue was €2.5 million, up 42% compared with the 3rd quarter of 2025.
- Gross margin was 63.1%, compared with 60.5% in the 3rd quarter of 2025, driven by spreading cost of goods sold over a higher volume of devices.
- Total operating loss was €21.9 million, compared with €24.4 million in the 3rd quarter of 2025. Cash, cash equivalents, and financial assets totaled €77.1 million as of September 30th, 2026, compared with €97.8 million at June 30th, 2026.
- Nyxoah trained 80 new U.S. surgeons in Q3, bringing the total to 342, and activated 53 new accounts, bringing the total to 233. A total of 447 patients were actively undergoing prior authorization in the Genio Access program entering the 4th quarter of 2026.
- The ACCESS U.S. pivotal study met its core primary efficacy and safety endpoints in patients with complete concentric collapse (CCC). At 12 months, the apnea-hypopnea index responder rate was 77.2% and the ODI responder rate was 87.7%, with zero device and procedure-related serious adverse events.
- Nyxoah submitted a PMA supplement to the FDA to expand Geneo’s U.S. indication to include CCC patients and initiated the BREATHE U.S. post-approval study.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Nyxoah Third Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Pearson Dennis, Investor Relations Associate. Please go ahead. Thank you.
Good afternoon, everyone, and I welcome you to our Third Quarter 2026 Earnings Call. Participating from the company today will be Liam Kelly, President and Chief Executive Officer, and Loïc Moreau, Interim Chief Financial Officer. During the call, we will discuss our operating activities and review our Third Quarter 2026 financial results, released after U.S. market closing today, after which we will host a question-and-answer session. The press release can be found on the Investor Relations section of our website. This call is being recorded and will be archived in the Events section on the Investor Relations tab of our website. Before we begin, I'd like to remind you that any statements that relate to expectations or predictions of future events, market trends, results, or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions.
These forward-looking statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon current available information, and the company assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these forward-looking statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our Form 20-F, which was filed with the Securities and Exchange Commission on March 26, 2026. With that, I will now turn the call over to Liam.
Thank you, Pearson. Good afternoon, everyone, and thank you for joining us. This is my first earnings call as President and Chief Executive Officer, and I am very pleased to be with you today. For those of you I have not yet met, let me briefly introduce myself. I bring more than 25 years of leadership experience in the medical technology industry, with a strong focus on commercial execution in the U.S. and international markets. During my time at Teleflex, I executed on significant product launches and expansions. These include products like EZ-IO, OnControl, GuideLiner, TrapLiner, Turnpike, UroLift, MANTA, Barrigel, and EZPLAZ. Many of these products are now the standard of care in their treatment modality. I also worked alongside a talented team to grow revenues, expand both growth and operating margins, and drive shareholder value.
Let me begin by thanking Olivier Taelman for his leadership over the past seven years. Olivier guided Nyxoah from clinical development through FDA approval and into our U.S. commercial launch. The foundation he and the team built is a large part of what drew me to this company. I am excited to join Nyxoah at this pivotal stage in the company's development for three primary reasons. First, Genio is a meaningfully differentiated therapy. Second, obstructive sleep apnea is a large and under-penetrated market. And third, we have a dedicated team that is capable of executing on our opportunity. I have had an excellent start to my time at Nyxoah. I have spent the last few weeks learning about the Genio product and its clinical differentiation, reviewing our go-to-market strategy, spending time with some key members of the team, and meeting some of our key customers to hear their perspective.
While it is still early in my onboarding process, a couple of things are clear. First, our employees are excellent. They are dedicated, driven, knowledgeable, and above all, patient-focused. They are eager to make Genio a successful product globally. They do not just want to be part of a great company; they want to help build a great company. Second, the Genio product is truly differentiated from the competition. It is the only bilateral HGNS therapy on the market. Our PMA submission, if approved, will not only allow us to serve more patients with complete concentric collapse, but will also significantly streamline the patient journey. CCC patients account for about one in four of the patients evaluated for this therapy and have no hypoglossal nerve stimulation option today in the United States. Third, we are executing well on our commercial launch in the U.S.
We have seen robust performance for a new product launch, and this is evidenced in our revenue trajectory. In addition, we continue to execute well in international markets. While I am still early in my new role, three short- to medium-term objectives are beginning to emerge. Number one is to refocus Nyxoah from an R&D and clinical development organization to a commercially centric organization. Number two is continuing to invest to drive penetration in the U.S. market while maintaining solid growth internationally. And number three is to continue to expand our gross margins and manage our operating expenses prudently. In summary, I believe there is substantial opportunity ahead for Nyxoah and that we have the right team to deliver the expected results as we work together to build a great company. Now, let me turn to a high-level overview of the third quarter.
U.S. net revenue was EUR 6.7 million, representing 29% sequential revenue growth. This is an acceleration from the 22% growth we achieved in the second quarter. Global net revenue was EUR 9.2 million, up 19% sequentially, and our international business continues to perform in line with our expectations. As we announced on October 19, we pre-announced revenue for the quarter and adjusted our full-year 2026 revenue guidance to a range of EUR 33 million-EUR 35 million. While we are disappointed to adjust our guidance, we are proud of the strong start to our commercial launch and acceleration in growth. The new guidance is based on U.S. revenues that are more reflective of historical ramps for a new technology, as physicians and centers build experience with Genio.
As I step into the role, I want to clarify that it is not our intent to systematically pre-announce our revenue on a quarterly basis. Despite the change in guidance, our foundations are strong. Physicians and OSA patients want a choice in hypoglossal nerve stimulation therapy. Genio is a differentiated product, and this has led to the growing number of trained surgeons and active accounts in the U.S., as well as positive feedback we receive on the Genio system. Our ACCCESS results and our PMA supplement submission could extend our differentiation in complete concentric collapse patients in the U.S. The U.S. launch remains the primary driver of our growth and our top priority. Our U.S. key performance indicators as of September 30, 2026, were strong. We trained 80 new surgeons in Q3, bringing the total to 342 surgeons trained on the Genio system.
We activated 53 new accounts in Q3, bringing the total to 233 active Genio accounts. We had 447 patients actively undergoing prior authorization in our Genio access program entering the fourth quarter of 2026. We continue to execute a focused launch. Today, we have 55 sales reps with 233 active accounts at the end of the third quarter. We will, of course, continue to activate new accounts, train new surgeons, but our focus on driving growth will be to go deeper in our existing accounts and drive utilization. Now for a reimbursement update. Our CMS and commercial payer coverage remain broad and stable, and our market access team continues to execute well on prior authorization submissions. In addition, CMS has published its final rule on 2027 reimbursement for the Genio procedure. Hospital outpatient reimbursement under C-code C8011 increases from $31,526 to $35,072, or approximately 11%.
Ambulatory surgical center reimbursement increases from $27,563 to $31,283, or approximately 13%. The facility increases strengthen the economic value of the Genio procedure. Clinical and regulatory progress was another highlight of the quarter. In September, we announced that our ACCCESS U.S. pivotal study met its core primary efficacy endpoints and its safety endpoints in patients with complete concentric collapse, or CCC. At 12 months, the Apnea-Hypopnea Index, or AHI, responder rate was 77.2%, and the ODI responder rate was 87.7%, both highly statistically significant, with zero device and procedure-related serious adverse events. The complete 12-month dataset was presented at the International Surgical Sleep Society annual meeting on October 15 and 16. CCC patients are currently contraindicated for commercially available unilateral hypoglossal nerve stimulation in the U.S. These OSA patients have limited treatment options today.
Genio has been approved for CCC patients in Europe since 2021, and we have now submitted a premarket approval, or PMA, supplement to the FDA to expand Genio's U.S. indication to include CCC patients. We have initiated a U.S. post-approval study called BREATHE, focused on building long-term real-world evidence for bilateral hypoglossal nerve stimulation in routine clinical practice. Now for an international update. We continue to execute in our focused markets with a disciplined approach. International revenue grew 42% compared to the third quarter of 2025. With that, I will now turn the call over to Loïc for a detailed review of our financial results.
Loïc? Thank you, Liam, and let me start with the top line.
For the third quarter of 2026, net revenue was EUR 9.2 million, 365% growth over the third quarter of 2025, and 19% sequential growth over the second quarter of 2026. U.S. net revenue was EUR 6.7 million, representing 29% sequential growth over the second quarter of 2026. International net revenue was EUR 2.5 million, 42% growth over the third quarter of 2025. Gross margin in the third quarter of 2026 was 63.1% compared to 60.5% in the third quarter of 2025. This improvement in gross margin is being driven by spreading our cost of goods sold over a higher volume of devices. Total operating loss for the third quarter of 2026 was EUR 21.9 million compared to EUR 24.4 million in the third quarter of 2025.
As we transition to a commercial enterprise, we are shifting our spending away from clinical and R&D and towards investment in our commercial infrastructure. We remain committed to being disciplined with our spending as we seek to reduce our cash burn quarter-over-quarter. In term of cash, as of September 30, 2026, cash equivalents, and financial assets totaled EUR 77.1 million compared to EUR 97.8 million at June 30, 2026. With regards to guidance, for the full year 2026, we expect global net revenue in the range of EUR 33 million-EUR 35 million. We expect gross margin for the full year 2026 to be in the range of 60%-62%. With that, I will turn the call back to Liam.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
5 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
